Share
TRUEinvivo® is pleased to announce that the patent for the DOSEmapper™ TLD bead strings and Automated DOSEmapper™ TLD Reader was granted in the USA on 26th November 2019. The patent number is 10,488,530.
Related Posts
TRUEinvivo's 2018 achievements include prototype development, patent filings, fundraising, multiple awards, and market expansion, setting the stage for a busy 2019.
Mount Vernon Cancer Centre pioneers first internal invivo dosimetry with TRUEnvivo® DOSEmapper™, revolutionising radiotherapy precision, patient safety, and treatment accuracy.
TrueInvivo's implant improves cancer treatment accuracy, accessible globally, supported by UKTI Sirius Programme.
Dr. Shakardokht Jafari presents DOSEmapper™ at IPEM conference after ESTRO, highlighting glass beads' innovation in dosimetry.
